Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Up 13.6% in January

Cellebrite DI Ltd. (NASDAQ:CLBT) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, a growth of 13.6% from the December 31st total of 1,030,000 shares. Currently, 1.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of Cellebrite DI

Several institutional investors have recently added to or reduced their stakes in CLBT. Handelsbanken Fonder AB purchased a new stake in Cellebrite DI during the fourth quarter worth about $3,937,000. New York State Common Retirement Fund grew its holdings in shares of Cellebrite DI by 2.6% in the fourth quarter. New York State Common Retirement Fund now owns 189,599 shares of the company’s stock valued at $4,177,000 after purchasing an additional 4,838 shares in the last quarter. Pembroke Management LTD increased its stake in Cellebrite DI by 4.4% during the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company’s stock worth $43,893,000 after buying an additional 84,087 shares during the period. Strategic Advisors LLC lifted its holdings in Cellebrite DI by 3.4% during the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company’s stock worth $641,000 after buying an additional 950 shares in the last quarter. Finally, Blue Trust Inc. purchased a new position in Cellebrite DI in the 4th quarter valued at approximately $468,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Up 2.5 %

NASDAQ:CLBT traded up $0.60 on Monday, reaching $24.64. The company’s stock had a trading volume of 1,404,701 shares, compared to its average volume of 1,526,417. Cellebrite DI has a 12-month low of $8.91 and a 12-month high of $24.89. The stock has a 50 day moving average price of $21.77 and a 200 day moving average price of $18.46. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of -15.89, a price-to-earnings-growth ratio of 3.55 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $106.90 million for the quarter, compared to analysts’ expectations of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. Cellebrite DI’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.09 earnings per share. Equities research analysts expect that Cellebrite DI will post 0.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CLBT. Needham & Company LLC raised their target price on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Craig Hallum upped their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $21.57.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.